A comparative study of the efficacy and safety of the original and generic orlistat in obese patients in the PROFIL register
https://doi.org/10.20996/1819-6446-2016-12-1-16-20
Abstract
Aim. To study the efficacy and safety of generic orlistat in comparison with the original drug in obese patients.
Material and methods. Patients with obesity degree 1-3 (n=60; 11.7% men and 88.3% women) were included into the open comparative randomized controlled study in parallel groups. After randomization 40 patients received of generic orlistat and 20 – the original orlistat. The duration of follow-up was 12 weeks. Changes in body weight, body mass index, and waist circumference were assessed, as well as the proportion of patients with a weight loss of 5-10% or more from baseline.
Results. Weight loss >5% was observed in 28 and 25% of patients in the groups of generic and original orlistat, respectively, and weight loss >10% - in 7.7% of patients only in the group of generic drug. No significant changes in blood pressure and heart rate were found. A significant reduction in total cholesterol and low density lipoprotein cholesterol was revealed. 11 (27.5%) adverse events were observed in the group of generic orlistat and 5 (25%) – in the group of original orlistat.
Conclusion. Generic orlistat 120 mg in capsules showed clinical equivalence to the original drug. Safety and tolerability of treatment with both drugs were comparable.
About the Authors
A. V. Zakharova
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Russian Federation
S. N. Tolpygina
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Russian Federation
V. P. Voronina
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Russian Federation
S. Yu. Martsevich
State Research Centre for Preventive Medicine. Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Russian Federation
References
1. WHO. Prevention and management оf the global epidemic оf obesity. Report оf the WНO Consultation оп Obesity (Geneva, 3-5 June, 1997). Geneva: WHO; 1997.
2. Obesity and overweight. Fact sheet N°311. Updated January 2015. Available at: http://www.who.int/mediacentre/factsheets/fs311/. Checked by 20.02.2016.
3. Butrova SA. Treatment of obesity. In: Melnichenko GA, eds. "Obesity". Moscow: MIA; 2004: 378-407. In Russian (Бутрова С.А. Терапия ожирения. В: Мельниченко Г.А., ред. «Ожирение». М.: МИА; 2004: 378-407).
4. Mancini M. C., Halpern A. Orlistat in the prevention of diabetes in the obese patient. Vascular Halth and Risk Management 2008:4(2) 352-36.
5. Kutishenko NP, Martsevich SY, Vashurina IV. What is the therapeutic equivalent (generic) and how to prove it. Ration Pharmacother Cardiol 2011; 7 (2): 241-5. In Russian (Кутишенко Н.П., Марцевич С.Ю., Вашурина И.В. Что такое терапевтическая эквивалентность (дженерика) и как ее доказать. Рациональная Фармакотерапия в Кардиологии 2011; 7(2): 241-5).
6. Martsevich SY, Kutishenko NP, Gaisenak OV, Tripkosh SG. The original drugs and generic drugs: an analysis of efficacy and safety with the help of well-controlled studies with the use of a register by the example of amlodipine. Kardiologiia 2013; 5: 83-6. In Russian (Марцевич С.Ю., Кутишенко Н.П., Гайсёнок О.В., Трипкош С.Г. Оригинальные препараты и дженерики: анализ эффективности и безопасности с помощью контролируемых исследований и с использованием регистра на примере амлодипина. Кардиология 2013; 5: 83-6).
7. Oganov RG, eds. Good clinical practice with the basics of evidence-based medicine. Tutorial. Moscow: Silitseya-Polygraph; 2011. In Russian (Оганов Р.Г., ред. Качественная клиническая практика с основами доказательной медицины. Учебное пособие. М.: Силицея-Полиграф; 2011).
8. Guerciolini R, Расе О, Zhi J. The effect оf orlistat (Хеniсаl) оn systemic lipase activities. Poster presented at the North American Association (or the Study оf Obesity (NAASO) Аnnuаl Congress, Саnсun, November 1997. Obesity Res 1997; 5(suppl 1): Abstract Р52.
Review
For citations:
Zakharova A.V., Tolpygina S.N., Voronina V.P., Martsevich S.Yu. A comparative study of the efficacy and safety of the original and generic orlistat in obese patients in the PROFIL register. Rational Pharmacotherapy in Cardiology. 2016;12(1):16-20. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-1-16-20
Views: 1054
Email this article 